ClinicalTrials.gg
Active, not recruitingNCT04851717Updated Jul 1, 2025

Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures

A Phase 2/3 interventional study of Remimazolam in Pediatric ALL, sponsored by Acacia Pharma Ltd. Active, not recruiting at 8 sites in 2 countries. Open to participants aged 0 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Acacia Pharma Ltd · Phase 2/3, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
0 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States — 168 open to participants now, 274 under way, 13 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States.

Planned enrollment
209th of 1,269
100 · median 35
Started
2021
with 35 others
Phase 2/3
14 of 1,545
none open now
Primary completion
2027-10
later than 160 of 272 live
Registered
1,328th of 1,545
by date

Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, this one is the 209th largest by planned enrollment of the 1,269 interventional ones that give a count, is one of 36 that started in 2021, is one of 14 in phase 2/3, reaches primary completion later than 160 of the 272 other live ones, and was the 1,328th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

168 of the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 0 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, or all of them as a file.
02

Study summary

To assess the efficacy of intravenous remimazolam in inducing and maintaining suitable sedation levels for paediatric patients undergoing diagnostic and/or therapeutic procedures

Read the detailed description

This trial is part of the European Paediatric Investigational Plan and the US Pediatric Study Plan and has been developed in line with guidance from the EMA Paediatric Committee and the US FDA.

The trial will commence with cohort 1 (aged ≥6 and \<18 years) and proceed to lower age groups: cohort 2 (≥3 and \<6 years); and, in European sites only, cohort 3 (full-term birth to \<3 years). The Data Monitoring committee (DMC) may convene any time after at least half of the subjects in cohort 1 or 2 have completed the study, to review PK,safety and efficacy data. If there are no concerns, the DMC may recommend to initiate concurrent dosing in the next younger cohort (cohort 2 or 3) in parallel to dosing the remaining subjects in cohort 1 or 2 Dosing for cohort 3 will be predicted based on PK modelling as well as efficacy and safety outcomes of the older age groups. Enrolment of patients aged \<2 years will not be permitted until supported by adequate juvenile toxicity data.

The trial will consist of three visits: Screening (Day -21 to day 1),Treatment (Day 1), and Follow-up (Day 4 [+3/-1 days]).

03

Conditions studied

04

Who can participate

Ages eligible
0 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form and/or assent and willingness of patient and parent(s) to participate in the trial.
  • In US sites: Paediatric male or female patients, aged ≥3 and \<18 years scheduled to undergo a diagnostic or therapeutic procedure, which is medically indicated and independent from the trial.
  • In European sites: Paediatric male or female patients, aged full term birth to \<18 years scheduled to undergo a diagnostic or therapeutic procedure, which is medically indicated and independent from the trial.
  • Maximum planned duration of procedure: 2 hours
  • ASA Physical Status I-III
  • Planned spontaneous breathing during sedation
  • A female who is of child bearing potential (i.e. after menarche) and sexually active must use a highly effective method of during the trial period (from the time of consent until all specified observations are completed)
  • Negative pregnancy test at screening and on treatment day -

Exclusion criteria

Exclusion Criteria:

  • Emergency procedures
  • Condition/procedure that requires planned airway control via endotracheal tube or LMA/IGEL insertion
  • Cranio-facial malformation, which would severely limit the possibilities for emergency airway rescue
  • Other abnormalities relating to the airway (including large tonsils and anatomical abnormalities of upper airway or lower airway) which may compromise emergency airway rescue
  • Known to benzodiazepines, flumazenil, dextran or any of the ingredients of the drug product
  • Known paradoxical reactions to benzodiazepines
  • History of sleep apnoea
  • Active respiratory failure
  • Active neuromuscular disease
  • Active cardiac failure
  • Active hepatic failure
  • Breast feeding females
  • Prohibited medication
  • Any patient judged by the Principal Investigator (PI) or Sub-Investigator to be inappropriate for the trial for any other reason
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    All Patients

    All paediatric patients undergoing diagnostic and/or therapeutic procedures

    Drug: Remimazolam

Interventions

06

What researchers measure

Primary outcomes

  1. Success of the procedure

    Success of the procedure defined as: Completion of the procedure AND no requirement for rescue sedative medication AND no requirement for more than the permitted bolus or infusion regimen

    Time frame: 2 hours

Secondary outcomes

  1. Target depth of sedation achieved

    Proportion of patients achieving predefined target depth of sedation (assessed using University of Michigan Sedation Score \[UMSS\]) during procedure

    Time frame: 2 hours

  2. Target range of sedation achieved during 80% of procedure duration

    Proportion of patients in whom predefined target range of sedation (assessed using University of Michigan Sedation Score \[UMSS\]) was achieved during at least 80% of procedure duration

    Time frame: 2 hours

  3. Percentage of time within target range of sedation

    Percentage of time spent by patients within predefined target range of sedation (assessed using University of Michigan Sedation Score \[UMSS\]) during procedure

    Time frame: 2 hours

  4. Adequacy of sedation

    Depth of sedation (assessed using Nurse Interpretation of Sedation Scale \[NISS\]) of patients over time

    Time frame: 2 hours

  5. Time to start of procedure

    Time between initial administration of study drug and start of procedure

    Time frame: 2 hours

  6. Time to fully alert

    Time between last dose of study drug, end of procedure and full alertness, defined as the first of three consecutive sedation scores showing no sedation

    Time frame: 2 hours

  7. Time to ready for discharge

    Time between last dose of study drug, end of procedure and discharge readiness

    Time frame: 2 hours

  8. Signs of re-sedation

    Occurrence, after reaching a University of Michigan Sedation Score (UMSS) of 0 after end of procedure, of a UMSS greater than zero

    Time frame: 2 hours

  9. Procedure success excluding cases where the procedure could not be completed for non sedative reasons

    Success of the procedure defined as: Completion of the procedure AND no requirement for rescue sedative medication AND no requirement for more than the permitted bolus or infusion regimen; excluding any patients where procedure was not completed for reasons other than failure of sedation

    Time frame: 2 hours

  10. Safety: AEs

    Incidence of treatment-emergent adverse events

    Time frame: 4 days

  11. Safety: emergence of delirium

    Incidence of paediatric anaesthesia emergence delirium between end of procedure until fit for discharge

    Time frame: 2 hours

  12. Safety: need for ventilation

    Incidence of use of any manual or mechanical ventilation

    Time frame: 2 hours

  13. Safety: need for reversal

    Incidence of use of flumazenil for reversal of benzodiazepine effect

    Time frame: 2 hours

  14. PK: assessment of plasma concentration-time relationship

    Graphical description of plasma concentration over time and comparison to predicted concentration-time relationship as calculated from existing pharmacokinetic/pharmacodynamic model

    Time frame: 3.5 hours

07

Study locations

8 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for Oct 2027, 71 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2021
First posted
Apr 20, 2021
StartActual
Nov 15, 2021
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04851717
Lead sponsor
Acacia Pharma Ltd
Collaborators
Paion UK Ltd.
Responsible party
Sponsor
First posted
Apr 20, 2021
Start date
Nov 15, 2021
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Jul 1, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remimazolam

Start the discussion